Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada ; volume:20 ; number:1 ; day:15 ; month:4 ; year:2020 ; pages:1-10 ; date:12.2020
BMC cancer ; 20, Heft 1 (15.4.2020), 1-10, 12.2020
- Urheber
-
Dai, Wei Fang
Beca, Jaclyn M.
Croxford, Ruth
Isaranawatchai, Wanrudee
Menjak, Ines B.
Petrella, Teresa M.
Mittmann, Nicole
Earle, Craig C.
Gavura, Scott
Hanna, Timothy P.
Chan, Kelvin K.W
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-020-06798-1
- URN
-
urn:nbn:de:101:1-2020062814063733572884
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Dai, Wei Fang
- Beca, Jaclyn M.
- Croxford, Ruth
- Isaranawatchai, Wanrudee
- Menjak, Ines B.
- Petrella, Teresa M.
- Mittmann, Nicole
- Earle, Craig C.
- Gavura, Scott
- Hanna, Timothy P.
- Chan, Kelvin K.W
- SpringerLink (Online service)
Ähnliche Objekte (12)
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study
Ipilimumab in patients with melanoma and autoimmune disease
Acute visual loss after ipilimumab treatment for metastatic melanoma
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma
MISIPI study: Melanoma ImmunoScore evaluation in patients treated with IPIlimumab
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)